Add BrightSurf on Google Email

University of California - Los Angeles Health Sciences


New targeting technology improves outcomes for patients with atrial fibrillation

A new targeting technology has been found to improve outcomes for patients with atrial fibrillation, with an 86% success rate after a single procedure. The technology, known as focal impulse and rotor modulation (FIRM), allows doctors to detect and shut down the electrical sources of the arrhythmia in minutes.

SourceUniversity of California - Los Angeles Health Sciences·JournalJournal of the American College of Cardiology·DateJul 18, 2012

UCLA study looks at why heart attacks cause so much more damage in late pregnancy

A new UCLA study published in Basic Research in Cardiology found that heart attacks in late pregnancy result in worse heart function and more damaged heart tissue than in non-pregnant females. The research suggests that the heart may be particularly vulnerable to injury during this critical period, but partially recovers after giving b...

SourceUniversity of California - Los Angeles Health Sciences·JournalBasic Research in Cardiology·DateJul 2, 2012

Drug combo much better than AZT alone at preventing mother-to-infant HIV transmission

A new UCLA-led study shows that a two- or three-drug combination given to infants within 48 hours of birth can reduce the risk of mother-to-child HIV transmission by about half compared to AZT alone. The study found that this combination significantly reduced HIV transmission, while also being less toxic to the infants.

SourceUniversity of California - Los Angeles Health Sciences·JournalNew England Journal of Medicine·DateJun 20, 2012

A better way to grow bone: Fresh, purified fat stem cells grow bone faster and better

Researchers at UCLA discovered that purified human perivascular stem cells can form bone faster and with higher quality than traditional methods, potentially eliminating the need for invasive bone grafts. The study uses a fresh cell composition called stromal vascular fraction to isolate and purify the stem cells.

SourceUniversity of California - Los Angeles Health Sciences·JournalStem Cells Translational Medicine·DateJun 11, 2012

Early PET response to neoadjuvant chemo predicts increased survival in sarcoma patients

A study by UCLA's Jonsson Comprehensive Cancer Center found that early Positron Emission Tomography (PET) response after neoadjuvant chemotherapy is associated with increased survival in patients with soft tissue sarcomas. Patients who showed a significant PET response had significantly longer survival rates compared to those who did not.

SourceUniversity of California - Los Angeles Health Sciences·JournalClinical Cancer Research·DateApr 2, 2012

UCLA scientists identify crucial cell and signaling pathway in placental blood stem cell niche

Researchers identified PDGF-B signaling in trophoblasts as a vital component of the placental niche, supporting blood stem cell generation and expansion without promoting differentiation. This discovery provides new insights into regulating EPO expression and governing the fates of blood stem cells during development.

UCLA brain-imaging technique predicts who will suffer cognitive decline over time

A UCLA-developed brain-imaging tool detects abnormal protein deposits associated with Alzheimer's disease and tracks progression over time. The technique, using FDDNP-PET scans, predicts cognitive decline in individuals with mild cognitive impairment and normal aging, offering potential early detection and treatment of Alzheimer's.

Quality of life for younger breast cancer patients more adversely affected than older women

A study published in the Journal of the National Cancer Institute found that younger breast cancer patients experience more severe mental health issues and physical impairments than older women. Researchers recommend educating these patients about potential post-treatment effects to reduce anxiety and improve quality of life.

SourceUniversity of California - Los Angeles Health Sciences·JournalJNCI Journal of the National Cancer Institute·DateJan 23, 2012